本研究旨在評估口服 azacitidine 於香港確診急性髓系白血病（AML）成人患者的真實世界療效及安全性。
適應症：Acute Myeloid Leukemia (AML)
收案條件
納入條件
- Documented diagnosis of Acute Myeloid Leukemia (AML).
- Achieved first complete response (CR) or complete response with incomplete blood recovery (CRi) following intensive induction chemotherapy.
- Not able or unwilling to undergo Hematopoietic Stem Cell Transplantation (HSCT).
- Received oral azacitidine as maintenance therapy after first CR or CRi following intensive induction chemotherapy in real-world settings (Note: CR/CRi status at oral azacitidine treatment initiation is left to the judgment of the local clinicians depending on the treatment response and the condition of the patient in routine clinical practices).
- Age ≥ 18 years at the index date (oral azacitidine initiation date).
排除條件
- Evidence of relapse prior to oral azacitidine initiation recorded in electronic health record (EHR).
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。